SUMMARY Background
Minimising placebo response is essential for drug development.
Aim
To conduct a meta-analysis to determine placebo response and remission rates in trials and identify the factors affecting these rates.
Methods
MEDLINE, EMBASE and CENTRAL were searched from inception to April 2014 for placebo-controlled trials of pharmacological interventions for Crohn's disease. Placebo response and remission rates for induction and maintenance trials were pooled by random-effects and mixed-effects meta-regression models to evaluate effects of study-level characteristics on these rates.
Results
In 100 studies containing 67 induction and 40 maintenance phases and 7638 participants, pooled placebo remission and response rates for induction trials were 18% [95% confidence interval (CI) 16 -21%] and 28% (95% CI 24-32%), respectively. Corresponding values for maintenance trials were 32% (95% CI 25-39%) and 26% (95% CI 19-35%), respectively. For remission, trials enrolling patients with more severe disease activity, longer disease duration and more study centres were associated with lower placebo rates, whereas more study visits and longer study duration was associated with higher placebo rates. For response, findings were opposite such that trials enrolling patients with less severe disease activity and longer study duration were associated with lower placebo rates. Placebo rates varied by drug class and route of administration, with the highest placebo response rates observed for biologics.
INTRODUCTION
The placebo effect, which describes the improvement in outcomes following a placebo intervention, has been well described in both organic and nonorganic gastrointestinal diseases. 1 Whilst the mechanisms underlying placebo response are incompletely understood, they are thought to be driven by complex neurobiological interactions of expectation and conditioning. 2 Specific factors that may influence placebo rates include spontaneous symptom fluctuation, natural variation in underlying disease, regression towards the mean, mode of treatment delivery, enhanced compliance with concomitant therapies and patient-provider relationships. 3, 4 In clinical practice, maximising placebo effects is desirable when treating patients with established therapies. 2 However, in drug development, minimising placebo effects is essential to efficiently detect true differences between an active treatment and placebo. Clinical trials in Crohn's disease (CD) have demonstrated heterogeneous and often large placebo rates 5 which may have hampered drug development. Su and colleagues previously conducted a meta-analysis of 30 RCTs and identified design features that influence placebo response and remission rates in CD trials. 6 Studies in that meta-analysis were conducted up to 2001, incorporated few biological therapies and included trials of antibiotics, which are no longer considered standard therapies for induction or maintenance of remission in CD. Previous reviews have focused on placebo rates in disease subtypes including trials of biologics, fistulising disease or post-operative prevention of relapse in CD. [7] [8] [9] [10] With evolving regulatory endpoints for clinical trials in CD, identifying trial design features that can yield predictable and low placebo rates is important to maximise assay sensitivity. Thus, we conducted a meta-analysis of placebo controlled trials in CD to estimate placebo response and remission rates for both induction and maintenance phase trials, as well as a meta-regression to identify trial design features influencing these rates.
MATERIALS AND METHODS

Search strategy and study selection
We searched MEDLINE (1948-May 2014), EMBASE (1947 ( -May 2014 , the Cochrane CENTRAL Register of Controlled Trials and the Cochrane Inflammatory Bowel Disease Review Group's Specialized Trials Register without language restriction from database inception to May 2014. The search strategies are reported in Appendix S1. Citations and abstracts of potentially relevant studies were selected and screened, and complete manuscripts were retrieved for assessment of eligibility. Abstracts from conference proceedings (Digestive Disease Week and United European Gastroenterology Week; 2012-2014) and bibliographies of relevant studies, review articles and meta-analyses were hand searched to identify additional trials.
Study eligibility criteria
Studies were eligible if they fulfilled the following criteria: (i) a placebo-controlled induction and/or maintenance trial of either a biological agent, immunosuppressant, corticosteroid or aminosalicylate in adults with active CD; (ii) use of the Crohn's Disease Activity Index (CDAI) 11 or Harvey-Bradshaw Index (HBI) 12 for enrolment and/or assessment of response/remission; (iii) duration of at least 2 weeks for induction, and 4 months for maintenance of remission trials. Trials which focused on fistulising disease were excluded, since examination of the placebo response in fistulising CD has been previously reported.
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Outcome assessment and data extraction Pairs of investigators independently assessed articles using the predefined inclusion criteria. Disagreements were resolved by consensus and discussion with a third reviewer (VJ). Data were extracted independently into a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA). The proportion of placebo patients with clinical response and remission were extracted as intention to treat. Other trial design features extracted included: (i) trial design and participant characteristics (number of treatment arms, trial development phase, year of publication, study location[s], first author nationality, number of participants, study duration, number of follow-up visits, frequency of follow-up visits, number of participants analysed, percentage of post-randomisation dropouts, mean age, gender ratio); (ii) type of intervention (drug class, concomitant therapy, dose, route of administration, frequency of administration, ratio of active drug to placebo; (iii) criteria for enrolment and outcome assessment (minimum CDAI/HBI score for inclusion; CDAI/HBIbased definitions of response and remission as prespecified in the primary trial); and (iv) disease severity and duration [baseline C-reactive protein (CRP), disease distribution, disease duration, prior surgery].
Data synthesis and statistical methods
Placebo response and remission rates were pooled using a random-effects model as applied to a rate on the logit scale for both induction and maintenance phases of trials. 13 Point estimates and associated 95% confidence intervals (CIs) on the logit scale were then converted back to the scale for proportions. This random-effects model was chosen to provide an inference about the average placebo rate in the population of studies from which the included studies are assumed to be a random selection. Stratum-specific rates of placebo response and remission for various patient and trial-level covariates were constructed to assess possible sources of heterogeneity. Mean values of study-level covariates included disease duration, disease severity, CDAI score on entry, and CRP level at enrolment; trial level covariates included setting, design, country of origin, drug class and route of administration, follow-up visits (duration and total number), publication year and definitions for response/remission. Statistical heterogeneity within these strata was quantified using Cochran's Q-statistic, and the magnitude was quantified using the I 2 statistic, 14, 15 with a value below 50% representing lower levels of heterogeneity. 16 Funnel plots were constructed to assess for potential publication bias related to placebo rates [17] [18] [19] by plotting the log odds against the standard error. Mixed meta-regression models were used to assess the effect of each study-level characteristic on placebo rates. 13 Assuming the existence of between study variability, these models used the logits of event rates as outcomes and study-level characteristics as predictors. Clinical judgement was used to establish factors for univariate metaregression analysis and were defined a priori. Factors with P-values less than 0.05 in univariate meta-regression were subjected to multivariable meta-regression analyses for the induction trials, while similar analyses for the maintenance trials were not conducted due to smaller number of trials to assess factors simultaneously.
A cumulative meta-analysis was also conducted by date of publication to assess the impact of a published study on the pooled overall rate based on previous studies. 20 Statistical analyses were performed using Metafor package 21 for R version 3.1.1.
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Risk of bias
The Cochrane Collaboration risk of bias tool was used to assess the methodological quality of the included studies. 23 Risk of bias items, including methods used to generate the randomisation schedule and conceal allocation, blinding, completeness of outcome data, evidence of selective outcome reporting and other potential sources of bias were independently assessed by author pairs.
RESULTS
Search results
The search yielded 7359 citations of which 2856 were duplicates and removed ( Figure S1 ). Of the remaining 4503 records screened, 501 full text articles were selected and reviewed for eligibility of which 331 reports of 100 trials were eligible for data extraction (including 67 induction phase studies, 40 maintenance phase studies and six post-operative prevention of recurrence studies (Figures 3 and 4) . Again, statistically significant heterogeneity was observed amongst these trials for both remission and response rates, with I 2 > 50%, P < 0.001.
For induction trials, using the less stringent CDAI definition of 70 point fall, the pooled placebo response rate was 37% (95% CI 32-43%) ( Figure 5) ; using a CDAI definition of 100 point fall, the pooled placebo response rate was 27% (95% CI 22-32%) ( Figure 6 ). For maintenance trials, using the less stringent CDAI definition of 70 point fall, the pooled placebo response rate was 25% (95% CI 16-38%) ( Figure 7) ; using a CDAI definition of 100 point fall, the pooled placebo response rate was 23% (95% CI 12-41%) ( Figure 8 ).
Five induction trials incorporated a definition of corticosteroid free remission/corticosteroid dosage reduction from baseline, in addition to a CDAI based endpoint. The pooled placebo remission rate for these five trials was 26% (95% CI 19-35%) ( Figure S5a ) and the pooled placebo response rate was 5% (95% CI 9-25%) ( Figure S5b) . Stratum specific placebo rates by trial design, setting, drug class and disease severity are shown in Tables S2 (induction trials) and S3 (maintenance trials).
Determinants of the placebo remission and response rate for induction trials Participant-and disease-related characteristics. For remission, there was no significant association between disease activity at baseline and placebo rates (26% vs. 16% for CDAI ≤250 vs. >300; OR 1.67, 95% CI 0.88-3.17, P = 0.25) ( Tables 1 and S2 ). Trials enrolling patients with longer disease duration were associated with significantly lower placebo remission rates (16% vs. 27% for >7 years vs. ≤7 years; OR 0.53, 95% CI 0.37-0.76, P < 0.001). No significant differences were observed for the pooled placebo remission rates according to CRP at trial entry (>10 vs. ≤10), disease distribution (ileal, colonic, ileo-colonic) or study-defined disease severity (mild-moderate vs. moderate-severe).
For response, findings were opposite to the results for remission. Trials enrolling patients with less severe disease based on the CDAI were associated with lower placebo rates (20% vs. 35% for CDAI 250-300 vs. >300; OR 0.56, 95% CI 0.37-0.85, P = 0.013 for covariate), with a 16% increase in the odds of placebo response for every 20-point increase in the CDAI (OR 1.16; 95% CI 1.07-1.2, P < 0.001). Similarly, a lower minimum CDAI score requirement for trial entry was associated with significantly lower placebo response rates (13% vs. 37% for CDAI ≤200 vs. ≥250; OR 0.38, 95% CI 0.17-0.88, P = 0.012).
Trial design and setting. For remission, increased duration of trial follow-up was associated with a significant increase in the pooled placebo rate (OR 1.02, 95% CI 1.01-1.03, P < 0.001; per 1-week increment) (Tables 1  and S2 ). Greater number of follow-up visits was also associated with an increase in the placebo remission rate (20% vs. 17% for >6 visits vs. ≤6 visits; OR 1.38, 95% CI 0.87-2.18, P = 0.17). Placebo remission rates were higher for single-centre trials compared to multi-centre, singlecountry trials (41% vs. 18%, respectively; OR 2.97, 95% CI 1.26-7.00; P = 0.026 for covariate), although no significant difference was seen between trials originating from Europe compared to North America (24% vs. 17%, respectively; OR 1.37, 95% CI 0.93-2.02; P = 0.20 for covariate) (Tables 1 and S2 ). There was a 1% reduction in the odds of achieving remission per extra centre in the trial (OR 0.99, 95% CI 0.99-1.00; P = 0.04).
For response, findings were opposite to the remission results. Increased duration of follow-up was associated with lower placebo rates, with a 2% reduction in the odds of response for every extra week of follow-up (OR 0.98, 95% CI 0.97-1.00, P = 0.046). No significant differences were observed according to number of study visits or continent of origin (Tables 1 and S2 ).
Class of drug. For remission, pooled placebo rates according to drug class ranged from 16% to 26% (Table S2 ). The highest placebo remission rate was observed for trials of corticosteroids (26%; 95% CI 16-39%; I 2 = 0.04) and the lowest for trials of biologicals (16%; 95% CI 14-19%; I 2 < 0.001), particularly among those administered intravenously (OR 0.60, 95% CI 0.39-0.94, P = 0.033 for covariate; baseline comparator topical route). Concurrent immunosuppressant use was associated with a lower odds of placebo remission (OR 0.52, 95% CI 0.31-0.88, P = 0.02). For response, the pooled placebo rate according to drug class ranged from 3% to 31% (Table S2 ). In contrast with the remission results, placebo rates were highest for biological trials (31%; 95% CI 28-36%) and lowest for trials of corticosteroids (3%; 95% CI 0-14%).
Determinants of placebo remission and response rates for maintenance trials Participant-and disease-related characteristics. For remission, trials enrolling patients with lower CDAI-based scores were associated with higher placebo rates (24.1% vs. Figure 1 | The pooled placebo remission rate (and 95% confidence interval) was calculated using a random-effects model. Based on 67 induction trials conducted between 1979 and 2014, the pooled placebo remission rate was 18% (95% CI 16-21%). Figure 2 | The pooled placebo response rate (and 95% confidence interval) for induction trials was calculated using a random-effects model. Based on 64 induction trials conducted between 1979 and 2014, the pooled placebo response rate was 28% (95% CI 24-32%).
44.8% for CDAI >300 vs. ≤250; OR 3.27, 95% CI 1.50-7.13, P = 0.002); each 20-point increase in the CDAI score at trial entry was associated with an 11% reduction in the odds of remission (OR 0.89; 95% CI 0.85-0.94, P < 0.001) ( Tables 2 and S3) . No significant differences were observed for the pooled placebo remission rates according to disease duration prior to enrolment (>7 years vs.
<7 years), CRP at trial entry (>10 vs. ≤10) or disease distribution (ileal, colonic, ileo-colonic). Use of concurrent immunosuppressants, a likely indicator of greater disease severity, was associated with a reduction in the odds of remission (OR 0.58; 95% CI 0.39-0.86, P = 0.007).
Counter to the placebo remission data, studies enrolling patients with less severe disease activity based on Figure 3 | The pooled placebo remission rate (and 95% confidence interval) for maintenance trials was calculated using a random-effects model. Based on 34 trials conducted between 1979 and 2013, the pooled placebo remission rate was 32% (95% CI 25-39%).
CDAI score were associated with lower placebo response rates (CDAI 250-300 vs. >300; OR 0.32, 95% CI 0.14-0.76, P = 0.001 for covariate).
Trial design and setting. For remission, trials published after 2005 were associated with lower placebo remission rates compared to those published before 2005 (24% vs. 38%, respectively; OR 0.49, 95% CI 0.27-0.89, P = 0.020). An increased number of trial centres was associated with a reduction in placebo remission rates, with a 1% reduction in the odds or remission per one centre increment (OR 0.99, 95% CI 0.99-1.00, P = 0.05). No significant differences were observed for the pooled placebo remission rates according to disease duration, number of follow-up visits or time point to measure remission. Figure 4 | The pooled placebo response rate (and 95% confidence interval) for maintenance trials was calculated using a random-effects model. Based on 15 trials conducted between 1995 and 2013, the pooled placebo response rate was 26% (95% CI 19-35%).
For response, an increased number of follow-up visits and increased duration of follow-up was associated with a reduction in placebo response rates. Each extra week of follow-up was associated with a 3% reduction in the odds of response (OR 0.97; 95% CI 0.95-0.99, P = 0.016) and each extra follow-up visit was associated Figure 6 | The pooled placebo response rate, defined as CDAI decreased by 100 points (and 95% confidence interval) for induction trials was calculated using a random-effects model. Based on 26 trials conducted between 1997 and 2013, the pooled placebo response rate was 27% (95% CI 22-32%).
with a 15% reduction in the odds of response (OR 0.86; 95% CI 0.76-0.97; P = 0.013).
Class of drug. For remission, pooled placebo rates by drug class ranged from 21% to 49% with the lowest placebo remission rate observed for biological agents (21% vs. 40% for corticosteroids; OR 0.39, 95% CI 0.18-0.86, P = 0.002 for covariate). Intravenous (OR 0.42, 95% CI 0.18-0.97, P = 0.011 for covariate; baseline comparator oral route) and subcutaneous routes (OR 0.41, 95% CI 0.21-0.80, P = 0.011 for covariate; baseline comparator oral route) of administration were associated with similar placebo remission rates for this drug class. The highest placebo remission rates were observed for clinical trials of aminosalicylates (49%; 95% CI 37-61%; I 2 = 0.001), followed by immunosuppressants (40%; 95% CI 25-56%; Figure 7 | Forest plot of pooled placebo response rates, defined as CDAI decreased by 70 points (and 95% confidence interval) for maintenance trials was calculated using a random-effects model. Based on seven trials conducted between 1999 and 2013, the pooled response rate was 25% (95% CI 16-38%). In contrast with the remission results, the highest placebo response rates were observed for trials of biological agents (28%, 95% CI 22-36%) and the lowest for immunosuppressants (6%; 95% CI 2-13%).
MULTIVARIABLE META-REGRESSION ANALYSIS
Multivariate meta-regression analysis identified trial setting (multi-centre, single country/multi-centre or multi-national/single centre) and drug class as factors significantly affecting remission rates. Similarly, for response, trial setting and drug class were also identified to significantly influence the placebo response rate (Table 3) . Sandborn Figure 8 | The pooled placebo response rate, defined as CDAI decreased by 100 points (and 95% confidence interval) for maintenance trials was calculated using a random-effects model. Based on six trials conducted between 1995 and 2007, the pooled response rate was 23% (95% CI 12-41%). 
Time trends in the placebo rates
The cumulative meta-analysis demonstrated a reduction in the cumulative pooled estimates of placebo remission rate from 1984 to 2001 (from 32% to 21%) that remained largely stable (18-21%) to 2014 ( Figure S2a) . Conversely, accumulative pooled placebo response rates consistently increased from 1997 to 2009 (from 8% to 28%), after which these rates remained constant (27-28%) to 2014 ( Figure S2b) .
Sources of heterogeneity, risk of bias and publication bias Heterogeneity among strata of relevant study features was slightly less evident in trials that evaluated a corticosteroid, had a minimum CDAI entry criteria of ≥250 and for studies conducted outside of North America or Europe (Table S2) . Risk of bias for induction studies was assessed as low or unclear for most parameters studied (Table S4 ). The asymmetry in the funnel plots for induction may suggest that smaller trials may have remained unpublished although formal statistical testing for asymmetry was non-significant ( Figure S3a and S3b).
DISCUSSION
In this large, contemporary meta-analysis of placebo response and remission rates in CD trials, our most notable findings are that placebo rates vary according to whether trials are designed for induction or maintenance, and the factors influencing placebo rates differ according to whether the trial endpoint is remission or response. For remission, trials enrolling patients with lower disease activity based on the CDAI (≤250 vs. >300) were associated with higher placebo rates for maintenance studies, however, this was not significant for induction studies. These findings reinforce the importance of ensuring that patients enrolled into clinical trials have sufficiently active disease. Failure to do so can jeopardise assay sensitivity and contribute to failure of drug development programmes. Similar findings were noted in a recent meta-analysis of placebo rates in ulcerative colitis (UC) RCTs, where higher endoscopic disease activity on the Mayo Clinic Score at enrolment was associated with lower placebo rates. 121 None of the trials in the current review used endoscopic criteria for study entry. However, several trials currently recruiting require centrally read endoscopic entry criteria, which may enable future research regarding its impact on placebo rates. Although regulatory authorities may move away from using the CDAI as an endpoint in clinical trials, it is notable that entry scores above 300 were associated with significantly lower placebo remission rates in the meta-regression. Whether alternatives to the CDAI, such as validated patient-reported outcome measures, 122 will be able to sufficiently differentiate active disease and moderate placebo rates remains to be determined, and is an issue of critical importance for drug development.
Other design features associated with higher placebo remission rates were a greater number of study followup visits and longer trial duration (2% increase in the odds of placebo remission per extra week of follow-up for induction studies). These findings are supported by the theory that increasing patient assessment and patient-provider interactions has a positive impact upon disease course, 2 and that with time, there is a greater chance of spontaneous improvement in disease state as well as regression towards the mean. Thus, minimising non-essential assessments within a clinical trial is an important design consideration. Fewer trial centres were also associated with higher placebo remission rates (1% reduction in the odds or remission per one centre increment) and the unreliability of treatment effects, particularly in single-centre trials, is well-recognised in the literature. 123, 124 The observation that longer disease duration was associated with significantly lower placebo remission rates is presumably due to a lower likelihood of achieving spontaneous remission with more established disease. An important and novel finding of this meta-analysis is that the factors influencing placebo response rates were often opposite to those identified for remission, both for induction and maintenance phase trials. Surprisingly, trials enrolling patients with less severe disease activity were associated with lower placebo response rates (20% vs. 35% for CDAI 250-300 vs. >300; OR 0.56, 95% CI 0.37-0.85 in induction trials). Similarly, increased duration of follow-up was associated with lower placebo response rates both for induction and maintenance phases, and increased number of follow-up visits was associated with a reduction in the odds of placebo response (14% reduction in the odds of response per extra follow-up visit for maintenance studies). These findings are counterintuitive, contrary with findings in UC clinical trials, 121 and suggest that the CDAI-based definition for response (>70 or >100 point decrease in CDAI) may be an unreliable endpoint for use in drug development. A notable example of the paradox between remission and response was observed in the phase 3 trial of vedolizumab for CD where there was a highly significant difference at week 6 between drug and placebo for remission (14.5% vs. 6.8%, P = 0.01), but not response (31.4% vs. 25.7%, P = 0.23). 59 The cumulative meta-analyses demonstrate that the cumulative pooled estimates of placebo rates of remission have been relatively stable from the year 2000 onwards. For response, however, these estimates have consistently increased since 1997. This corresponds with the finding that the highest placebo response rates by drug class were observed for biologicals, and the majority of trials since 1997 have assessed these agents. 'Response expectancy' 1, 125 may be greater for patients enrolled in biological trials, and this may in turn be reflected in placebo rates when a disease activity score that incorporates patient-and physician-reported elements such as the CDAI is used. Further reductions in CD trial placebo rates are likely to require the routine measurement of objective measures of inflammation. Centrally read endoscopy at trial enrolment has the potential to increase trial efficiency by reducing overestimation of lesion severity by site readers. 126 As an outcome measure endoscopy may allow for more precise characterisation of treatment response through consistent scoring by expert readers. Other objective measures of disease activity such as magnetic resonance enterography (MRE) also hold potential once their operating properties have been formally evaluated. Significant heterogeneity was demonstrated both for induction and maintenance trials when pooled for response and remission (I 2 P value for both outcomes <0.001) despite stratification across several covariates, although this factor was less prominent for trials that evaluated a corticosteroid, had a minimum CDAI entry criteria of ≥250 and for studies conducted outside of North America or Europe. This level of heterogeneity was surprising given that the eligibility criteria were restricted to only include trials using the CDAI or HBI score, and that outcome definitions for response and remission were broadly similar. This observation highlights that many other factors contribute to heterogeneity including patient demographics, patterns of disease, timing and methods of outcome assessment and other characteristics of the study population (e.g. concomitant medications). Further investigation of the influence of patient characteristics on heterogeneity would require comparison of subgroups within every trial and then combining these across trials. This was not possible in our study and would require access to individual participant trial data. The degree of heterogeneity observed, however, is in keeping with that observed in previous reviews of this topic. [6] [7] [8] [9] [10] Su and colleagues conducted a meta-analysis of 30 placebo-controlled trials published up to 2001 that used the CDAI. 6 The main finding of this study was that study duration, number of follow-up visits and CDAI entry score most strongly influenced placebo rates. 6 Whilst there were similar results in the present analysis of 100 studies, the main difference that we observed was the consistently opposite results for the factors influencing remission compared to response. In addition, we assessed placebo rates for induction and maintenance phases separately, which provides new data for the design of clinical trials. The strengths of this study include its size, provision of pooled and cumulative estimates of placebo response and remission both for induction and maintenance phases, and detailed assessment of covariates influencing placebo rates. The study also has some limitations. First, no trials routinely utilised central reading of endoscopy for enrollment, thus we were unable to evaluate the impact of this methodology on placebo rates as has been done in UC. Second, there was significant heterogeneity when data were pooled both for induction and maintenance trials. Third, the study may have limited power to evaluate the effect of some characteristics given that CRP, a covariate which is known to differentiate active inflammation, was not identified as a factor influencing placebo rates in the meta-regression. Fourth, the methodology of meta-regression to investigate whether study characteristics may explain heterogeneity within a systematic review can be prone to false-positive results. 127 In conclusion, placebo response and remission rates in CD trials vary according to whether trials are designed for induction or maintenance of remission or response. For remission, lower disease entry criteria, more followup visits and longer trial duration increased placebo rates, whereas longer disease duration lowered them. Conflicting results were observed for remission vs. response rates, suggesting that response may be an unreliable endpoint in RCTs. These contemporary pooled and cumulative data will help to inform sample size calculations and design decisions for future placebocontrolled RCTs in CD.
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